Management of patients with hereditary medullary thyroid carcinoma

European Journal of Pediatric Surgery

Volumn 14, Issue 6, 2004, Pages 375-383

  Fitze, Guido ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Endocrinology; Mutation; Prophylaxis; RET proto oncogene; Surgery

Indexed keywords

CANCER SURGERY; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC DISORDER; GENETIC SCREENING; HEREDITY; HUMAN; MEN2 GENE; MOLECULAR GENETICS; MULTIGENE FAMILY; PROPHYLAXIS; PROTO ONCOGENE; REVIEW; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

CARCINOMA, MEDULLARY; CHROMOSOME MAPPING; CYSTEINE; GENETIC COUNSELING; HIRSCHSPRUNG DISEASE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION, MISSENSE; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; RISK ASSESSMENT; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 11244327813     PISSN: 09397248     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-821209     Document Type: Review

References (66)

1. Angrist M, Bolk S, Thiel B, Puffenberger EG, Hofstra RM, Buys CHCM, Cass DT, Chakravarti A. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. Hum Mol Genet 1995; 4: 821-830
2. Attie T, Pelet A, Edery P, Eng C, Mulligan LM, Amiel J, Boutrand L, Beldjord C, Nihoul-Fékété C, Munnich A, Ponder BAJ, Lyonnet S. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet 1995; 4: 1381-1386
3. Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS, Leitner ML, Araki T, Johnson EM Jr, Milbrandt J. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRα3-RET receptor complex. Neuron 1998; 21: 1291-1302
4. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grußendorf M, Raue F, Ritter M, Höppner W. A new hot spot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2 A. J Clin Endocrinol Metab 1998; 83: 770-774
5. Blank RD, Sklar CA, Dimich AB, LaQuaglia MP, Brennan MF. Clinical presentation and Ret proto-oncogene mutations in seven multiple endocrine neoplasia type 2 kindreds. Cancer 1996; 78: 1996-2003
6. Blaugrund JE, Johns MM, Eby YJ, Ball DW, Baylin SB, Hruban RH, Sidransky D. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet 1994; 3: 1895-1897
7. Borrego S, Eng C, Sanchez B, Saez ME, Navarro E, Antinolo G. Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2 A and Hirschsprung disease. J Clin Endocrinol Metab 1998; 83: 3361-3364
8. Borrego S, Saez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antinolo G, Eng C. Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 1999; 36: 771-774
9. Borrego S, Ruiz A, Saez ME, Gimm O, Gao X, Lopez-Alonso M, Hernandez A, Wright FA, Antinolo G, Eng C. RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease. J Med Genet 2000; 37: 572-578
10. Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ, Arighi E, Miranda C, Eng C, Alberti L, Bocciardi R, Mondellini P, Scopsi L, Romeo G, Ponder BAJ, Pierotti MA. RET activation by germline MEN2A and MEN2B mutations. Oncogene 1995; 11: 2419-2427
11. Borst MJ, VanCamp JM, Peacock ML, Decker RA. Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. Surgery 1995; 117: 386-391
12. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJM, Lombardi G, Manelli M, Pacini F, Ponder BAJ, Raue F, Skogseid B, Tamburano G, Thakker RV, Thompson NW, Tomasetti P, Tonelli F, Wells Jr. SA, Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-5671
13. Brooks-Wilson AR, Smailus DE, Goodfellow PJ. A cluster of CpG islands at D10S94, near the locus responsible for multiple endocrine neoplasia type 2A (MEN2A). Genomics 1992; 13: 339-343
14. Carlomagno F, De Vita G, Berlingieri MT, de Franciscis V, Melillo RM, Colantuoni V, Kraus MH, Di Fiore PP, Fusco A, Santoro M. Molecular heterogenity of RET loss of function in Hirschsprung's disease. EMBO J 1996; 15: 2717-2725
15. Caron P, Attie T, David D, Amiel J, Brousset F, Roger P, Munnich A, Lyonnet S. C618 R mutation in exon 10 of the Ret proto-oncogene in a kindred with multiple endocrine neoplasia type 2 A and Hirschsprung diease. J Clin Endocrinol Metab 1996; 81: 2731-2733
16. Chappuis-Flament S, Pasini A, De Vita G, Segouffin-Cariou C, Fusco A, Attie T, Lenoir GM, Santoro M, Billaud M. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines. Oncogene 1998; 17: 2851-2861
17. Chretien P, Blanchard L, Gaboury L, Lacroix A, Verdy M, Villeneuve L. Cosegregation of Hirschsprung disease (HSCR) and a Ret mutation in a French Canadian family with MEN-2 A. Am J Hum Genet 1994; 55: A357
18. Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MA, Laimore TC, Doherty GM, Balfe DM, Wells SA, Moley JF. Gastrointestinal manifestation of multiple endocrine neoplasia type 2. Ann Surg 2002; 235: 648-655
19. Davenport MP, Ward RL, Hawkins NJ. The null oncogene hypothesis and protection from cancer. J Med Genet 2002; 39: 12-15
20. Decker RA, Peacock ML, Watson P. Hirschsprung disease in MEN 2 A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet 1998; 7: 129-134
21. Dralle H, Gimm O, Simon D, Frank-Raue K, Görtz G, Niederle B, Wahl RA Koch B, Walgenbach S, Hampel R, Ritter MM, Spelsberg F, Heiss A, Hinze R, Höppner W. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 1998; 22: 744-751
22. Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L, Holder S, Nihoul-Fékété C, Ponder BA, Munnich A. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994; 367: 378-379
23. Eng C. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. New Engl J Med 1996; 335: 943-951
24. Fitze G, Schreiber M, Kuhlisch E, Schackert HK, Roesner D. Association of RET protooncogene codon 45 polymorphism with Hirschsprung disease. Am J Hum Genet 1999; 65: 1469-1473
25. Fitze G, Cramer J, Ziegler A, Schierz M, Schreiber M, Kuhlisch E, Roesner D, Schackert HK. Association between c135G/A genotypes and RET proto-oncogene germline mutations and phenotype of Hirschsprung's disease. Lancet 2002; 359: 1200-1205
26. Fitze G, Schierz M, Bredow J, Saeger HD, Roesner D, Schackert HK. Various penetrante of familial medullary thyroid carcinoma in patients with RET proto-oncogene codon 790/791 germline mutations. Ann Surg 2002; 236: 570-575
27. Fitze G, Appell H, König IR, Görgens H, Stein U, Walther W, Gossen M, Schreiber M, Ziegler A, Roesner D, Schackert HK. Functional haplotypes of the RET proto-oncogene promoter are associated with Hirschsprung disease (HSCR). Hum Mol Genet 2003; 12: 3207-3214
28. Fitze G, Schreiber M, Hohenberger W, Hümmer HP, Roesner D, Schackert HK. Interaction of RET proto-oncogene codon 609 germline mutations with RET haplotypes characterized by c.135 G > A alleles modifying MEN 2 A or HSCR phenotypes. Am J Med Genet DOI: 10.1002/ajung.a30230
29. Frohnauer MK, Decker RA. Update on the MEN 2 A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery 2000; 128: 1052-1058
30. Gardner E, Papi L, Easton DF, Cummings T, Jackson CE, Kaplan M, Love DR, Mole SE, Moore JK, Mulligan LM, Norum RA, Ponder MA, Reichlin S, Stall G, Telenius H, Telenius-Berg M, Tunnacliffe A, Ponder BAJ. Genetic linkage studies map the multiple endocrine neoplasia type 2 loci to a small interval on chromosome 10q11.2. Hum Mol Genet 1993; 2: 241-246
31. Gill JR, Reyes-Mugica M, Iyengar S, Kidd KK, Touloukian RJ, Smith C, Keller MS, Genel M. Early presentation of metastatic medullary cancer on multiple endocrine neoplasia, type IIA: implications for therapy. J Pediatr 1996; 129: 459-464
32. Gimm O, Niederle BA, Weber T, Bockhorn M, Ukkat J, Brauckhoff M, Thang PN, Frilling A, Klar E, Niederle B, Dralle H. RET proto-oncogene mutations affecting codon 790/791: a mild form of multiple endocrine neoplasia 2 A? Surgery 2002; 132: 952-959
33. Hahn M, Bishop J. Expression pattern of Drosophila ret suggests a common ancestral origin between the metamorphosis precursors in insect endoderm and the vertebrate enteric neurons. Proc Natl Acad Sci USA 2001; 98: 1053-1058
34. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Höppener JWM, Ploos van Amstel HK, Romeo G, Lips CJM, Buys CHCM. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2 B and sporadic medullary thyroid carcinoma. Nature 1994; 367: 375-376
35. Hofstra R. Minisymposium: Multiple endocrine neoplasia type 1. J Intern Med 1998; 243: (abstract 231)
36. Huang SC, Koch CA, Vortmeyer AO, Pack SD, Lichtenauer DU, Mannan P, Lubensky IA, Chrousos GP, Gagel RF, Pacak K, Zhuang Z. Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple enocrine neoplasia type 2-associated pheochromocytoma. Cancer Res 2000; 60: 6223-6226
37. Huang SC, Torres-Cruz J, Pack SD, Koch CA, Vortmeyer AO, Mannan P, Lubensky IA, Gagel RF, Zhuang Z. Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 459-463
38. Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G, Takahashi M. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2 A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res 1997; 57: 2870-2872
39. Kambouris M, Jackson CE, Feldmen GL. Diagnosis of multiple endocrine neoplasia (MEN) 2 A, 2 B and familial medullary thyroid cancer (FMTC) by multiplex PCR and heteroduplex analysis of RET proto-oncogene mutations. Hum Mutat 1996; 8: 64-70
40. Kitamura Y, Goodfellow PJ, Shimizu K, Nagahama M, Ito K, Kitagawa W, Akasu H, Takami H, Tanaka S, Wells Jr SA. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC. Oncogene 1997; 14: 3103-3106
41. Maniè S, Santoro M, Fusco A, Billaud M. The RET receptor: Function in development and dysfunction in congenital malformation. Trends Genet 2001; 17: 580-589
42. Marsh DJ, Robinson BG, Andrew S, Richardson AL, Pojer R, Schnitzler M, Mulligan LM, Hyland VJ. A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2 A and familial medullary thyroid carcinoma families. Genomics 1994; 23: 477-479
43. Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R, Richardson A-L, Houghton C, Mulligan LM, Ponder BAJ, Robinson BG. Germline and somatic mutations in an Oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 1996; 56: 1241-1243
44. McMahon R, Mulligan LM, Healey CS, Payne SJ, Ponder M, Ferguson-Smith MA, Barton DE, Ponder BA. Direct, non-radioactive detection of mutations in multiple endocrine neoplasia type 2 A families. Hum Mol Genet 1994; 3: 643-646
45. Mole SE, Mulligan LM, Healey CS, Ponder BAJ, Tunnacliffe A. Localization of the gene for multiple endocrine neoplasia type 2 A to a 480 kb region in chromosome band 10q11.2. Hum Mol Genet 1993; 2: 247-252
46. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BA. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2 A. Nature 1994; 363: 458-460
47. Mulligan LM, Eng C, Attie T, Lyonnet S, Marsh D, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A, Venter DJ, Munnich A, Ponder BAJ. Diverse phenotype associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 1994; 3: 2163-2167
48. Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S, Kottler ML, Morange S, Conte-Devolx B. Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab 2001; 86: 3747-3753
49. Pasini B, Hofstra RMW, Yin L, Bocciardi R, Santamaria G, Grootscholten PM, Ceccherini I, Patrone G, Priolo M, Buys CHCM, Romeo G. The physical map of the human RET proto-oncogene. Oncogene 1995; 11: 1737-1743
50. Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, Rudkin BB, Schuffenecker I, Lenoir GM, Billaud M. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 1997; 15: 393-402
51. Pasini B, Rossi R, Ambrosio MR Zatelli MC, Gullo M, Gobbo M, Collini P, Aiello A, Pansini G, Trasforini G, Uberti EC. RET mutation profile and variable clinical manifestation in a family with multiple endocrine neoplasia type 2 A and Hirschsprung's disease. Surgery 2002; 131: 373-381
52. Pelet A, Geneste O, Edery P, Pasini A, Chappuis S, Attie T, Munnich A, Lenoir G, Lyonnet S. Billaud M. Various mechanisms cause RET-ligand signaling defects in Hirschsprung's disease. J Clin Invest 1998; 101: 1415-1423
53. Peretz H, Luboshitsky R, Baron E, Bitot A, Gershoni R, Usher S, Grynberg E, Yakobson E, Graff E, Lapidot M. Cys 618 Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting. Hum Mutat 1997; 10: 155-159
54. Punales MK, Graf H, Gross JL, Maia AL. RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J Clin Endocr Metab 2003; 88: 2644-2649
55. Robledo M, Gil L, Pollan M, Cebrian A, Ruiz S, Azanedo M, Benitez J, Menarguez J, Rojas JM. Polymorphisms G691 S/S904 S of RET as genetic modifiers of MEN 2 A. Cancer Res 2003; 63: 1814-1817
56. Romeo G, Ronchetto P, Luo Y, Barone V, Seri M, Ceccherini I, Pasini B, Bocciardi R, Lerone M, Kääriäinen H, Martuciello G. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 1994; 367: 377-378
57. Romeo G, Ceccherini I, Celli J, Priolo M, Betsos N, Bonardi G, Seri M, Yin L, Lerone M, Jasonni V, Martucciello G. Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. J Intern Med 1998; 243: 515-520
58. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP. Activation of RET as a dominant transforming gene by germline mutations of MEN 2 A and MEN 2 B. Science 1995; 267: 381-383
59. Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, Calmettes C, Modigliani E, Lenoir GM. RET proto-oncogene mutations in French MEN 2 A and FMTC families. Hum Mol Genet 1994; 3: 1939-1943
60. Schuffenecker I, Ginet N, Goldgar D, Eng C, Chambe B, Boneu A, Houdent C, Pallo D, Schlumberger M, Thivolet C, Lenoir GM. Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2 A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. Am J Hum Genet 1997; 60: 233-237
61. Schuringa JJ, Wojtachnio K, Hagens W, Vellenga E, Buys CHCM, Hofstra R, Kruijer W. MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene 2001; 20: 5350-5358
62. Seri M, Yin L, Barone V, Bolino A, Celli I, Bocciardi R, Pasini B, Ceccherini I, Lerone M, Kristofferson U, Larsson LT, Casasa JM, Cass DT, Abramowicz MJ, Vanderwinden JM, Kravcenkiene I, Baric I, Silengo M, Martuciello G, Romeo G. Frequency of RET mutations in long- and short-segment Hirschsprung disease. Hum Mutat 1997; 9: 243-249
63. Takahashi M, Ritz J, Cooper GM. Activation of a Novel Human Transforming Gene, ret, by DNA Rearrangement. Cell 1985; 42: 581-588
64. Takahashi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, Billaud M. Co-segregation of MEN 2 and Hirschsprung's disease: The same mutation of RET with Gain and Loss-of-function? Hum Mutat 1999; 13: 331-336
65. Wells SA, Chi DD, Toshima D, Dehner LP, Coffin CM, Darton B, Ivanovitch JL, DeBenedetti MK, Dilley WG, Moley JF, Norton JA, Donis-Keller H. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2 A. Ann Surg 1994; 200: 237-250
66. van Heurn LWE, Schaap C, Sie G, Haagen AAM, Gerver WJ, Freling G, van Amstel PHK, Heinemann E. Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg 1999; 34: 568-571